|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Introduction of a tumor antigen-specific T cell receptor (TCR) into patient-derived lymphocytes has already exhibited promising results for the treatment of melanoma and other malignancies in clinical trials.
|
31207210 |
2019 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival.
|
29744371 |
2018 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
|
29325699 |
2018 |
|
LINC01194
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
In summary, MAP kinase inhibitors (MAPKi) strongly alter the tumor antigen expression profile over time, favoring evolution of melanoma variants cross-resistant to both T cells and MAPKi.
|
30221038 |
2018 |
|
LINC01194
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
The results indicated that EGF G1380A and bFGF C754G gene polymorphisms were associated with the susceptibility and prognosis of malignant melanoma, and that the polymorphisms of EGF G1380A and bFGF C754G as well as the haploid TAG increased the susceptibility of malignant melanoma.
|
28219779 |
2017 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Discrepancy Between Tumor Antigen Distribution and Radiolabeled Antibody Binding in a Nude Mouse Xenograft Model of Human Melanoma.
|
28380302 |
2017 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
In addition, we discuss the roles of emerging molecular players that are involved in melanoma pathogenesis, including the functional role of the melanoma tumor antigen, p97/MFI2 (melanotransferrin).
|
26844774 |
2016 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Here, we determined that TIGIT is upregulated on tumor antigen-specific (TA-specific) CD8⁺ T cells and CD8⁺ tumor-infiltrating lymphocytes (TILs) from patients with melanoma, and these TIGIT-expressing CD8⁺ T cells often coexpress the inhibitory receptor PD-1.
|
25866972 |
2015 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Although melanoma vaccines stimulate tumor antigen-specific CD8(+) T cells, objective clinical responses are rarely observed.
|
24343228 |
2014 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
The tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4) appears to be a useful biomarker to identify melanoma cells and an attractive target to apply antibody-based immunotherapy for the treatment of melanoma.
|
24258997 |
2014 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These results suggest that the efficacy of melanoma DC-based immunotherapy is enhanced when tumor antigen-loaded DCs used for vaccination express cPs.
|
23934126 |
2013 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Adoptive transfer of tumor-antigen-specific T(H)9 cells into both WT and Rag1(-/-) mice suppressed melanoma growth; this effect was abrogated by treatment with neutralizing antibodies to IL-9.
|
22772464 |
2012 |
|
LINC01194
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators.
|
22850568 |
2012 |
|
LINC01194
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
To investigate this, we determined the specificity of T cells from melanoma patients treated with DCs loaded with mRNA encoding a full-length tumor antigen fused to a signal peptide and an HLA class II sorting signal, allowing presentation in HLA class I and II.
|
22371843 |
2012 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Our study focuses on analyzing the effect of HER2 on MHC class I antigen presentation and sensitivity to tumor-antigen specific cytotoxic T lymphocytes (CTLs) in HLA-A2.1(+) melanoma cell lines.
|
20715101 |
2011 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
As tumor antigen-specific CD4+ T cells can mediate strong therapeutic anti-tumor responses in melanoma patients we set out to establish a comprehensive screening strategy for the identification of tumor-specific CD4+ T cell epitopes suitable for detection, isolation and expansion of tumor-reactive T cells from patients.
|
21152437 |
2010 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
It is approximately 3.5x10(5)/ml collagen-fibrin gel in vitro and approximately 3x10(6)/ml or /g melanoma for previously published studies of ex vivo-activated adoptively transferred tumor antigen-specific CD8+ T cell killing of cognate antigen-expressing melanoma cells in established tumors in vivo.
|
20065066 |
2010 |
|
LINC01194
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
Canine malignant melanoma (CMM) resembles human malignant melanoma in terms of metastatic behavior, refractoriness to standard therapy, and tumor antigen expression but it is largely unknown how CMM resembles human melanoma with regard to molecular pathogenesis and cellular signaling.
|
19949352 |
2010 |
|
LINC01194
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
TriMix DCs coelectroporated with whole tumor-antigen mRNA stimulate antigen-specific T cells in vitro and induce antigen-specific T-cell responses in melanoma patients through vaccination.
|
19417017 |
2009 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Therefore, TAP expression restores both antigen presentation and immunogenicity in A375 melanoma cells and concomitantly increases IL-12 and IFN-gamma production in tumor antigen-specific CTLs; TAP should be considered as a part of the immunotherapies for MM.
|
18385764 |
2008 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These results indicate that TAG-derived peptides may be good components of a therapeutic vaccine designed to target melanoma and a variety of epithelial cell-derived malignancies.
|
18157007 |
2008 |
|
LINC01194
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Melanotransferrin (MTf) or melanoma tumor antigen p97 is a transferrin (Tf) homolog that is found predominantly bound to the cell membrane via a glycosyl phosphatidylinositol anchor.
|
17452986 |
2007 |
|
LINC01194
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo.
|
17449903 |
2007 |
|
LINC01194
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
Tumor antigen expression in melanoma varies according to antigen and stage.
|
16467087 |
2006 |
|
LINC01194
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
|
16645618 |
2006 |